top cx logo
cx logo
Explorearrow down
search icon
Explore
arrow down

French firm trials artificial heart

First operation in Paris "went satisfactorily" company says

A FRENCH biomedical firm has begun the first human trial of its prototype artificial heart, which aims at overcoming shortages of organs available for transplant.

The implant operation by Carmat, which took place at the Georges Pompidou Hospital in Paris, "went satisfactorily," it said in a statement.

The patient, whom it did not name, is in intensive care, "is conscious and speaking to relatives," Carmat said, adding that it was too early to draw wider conclusions about the operation.

Artificial hearts have been in use for many years as a temporary fix for patients with chronic heart problems.

Tens of thousands of people with hearts damaged by disease or a heart attack die each year because of a lack of a donor.

The Carmat product aims at providing a longer-term solution to bridge the wait and enable hospitalised patients to return home and maybe even resume work.

A self-contained unit implanted in the patient's chest, it uses soft "biomaterials" and an array of sensors, rather than a pump, to mimic the contractions of the heart.

The goal is to lessen the risk of blood clots and rejection by the immune system.

Power comes from an external source or wearable lithium batteries.

The company was authorised in September by French health watchdogs to carry out four trials in three hospitals after tests on animals.

The 900g device is the outcome of a years-long collaboration between cardiac surgeon Alain Carpentier and the European aerospace giant EADS.

Nearly 100,000 people in Europe and the United States are in need of a heart transplant, according to Carmat.

The price of the heart is estimated at between €140,000 and €180,000.

Phase I of the trial, on the small group of volunteers in terminal condition, will assess survival one month after the operation, or earlier if the patient receives a natural heart.

If all goes well, a second phase, conducted among a group of about 20 patients, will look at efficacy - quality of life, comfort and side effects - as well as safety.

Text:AFP/Relaxnews. Photo: shutterstock/Sebastian Kaulitzki/shutterstock.com

Resident or second-home owner in France?
Benefit from our daily digest of headlines and how-to's to help you make the most of life in France
By joining the newsletter, you agree to our Terms & Conditions and Privacy Policy
See more popular articles
The Connexion Help Guides
featured helpguide
Healthcare in France*
Featured Help Guide
- Understand the French healthcare system, how you access it and how you are reimbursed - Useful if you are new to the French healthcare system or want a more in-depth understanding - Reader question and answer section Aimed at non-French nationals living here, the guide gives an overview of what you are (and are not) covered for. There is also information for second-home owners and regular visitors.
Get news, views and information from France
You have 2 free subscriber articles left
Subscribe now to read unlimited articles and exclusive content
Already a subscriber? Log in now